A stark transatlantic regulatory split leaves patients in one hemisphere stranded without critical therapies.
Differing regulatory risk tolerances and data interpretations between the FDA and European authorities create a geographical divide where patients are denied access to approved treatments.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The EMA's refusal of narsoplimab leaves European transplant patients without a therapeutic option that has been approved and available in the US for months.
Tolebrutinib achieved landmark approval in Europe for nrSPMS disability progression while its application remains indefinitely stalled before the FDA.
Differing administrative flexibilities between the FDA and EMA forced the complete withdrawal of the European application while the US review remains on track.
The negative opinion from European regulators on narsoplimab halts its commercial path in Europe despite its existing approval in the United States.
A sharp regulatory split leaves European TA-TMA patients without access to a therapy already approved and available in the United States.